# 2026-16999: FDA renews panel to advise on heart and kidney pills

2026-16999, Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-08-20, effective Authority for the Cardiovascular and Renal Drugs Advisory Committee will expire on August 27, 2026, unless the Commissioner formally determines that renewal is in the public interest. (as of 2026-08-27).

- Canonical: https://policyrisk.com/federal-register/2026-16999
- As of: 2026-08-27
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16999
- Title: Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 53882
- Published: 2026-08-20
- Effective: Authority for the Cardiovascular and Renal Drugs Advisory Committee will expire on August 27, 2026, unless the Commissioner formally determines that renewal is in the public interest.
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-08-27

## In one line

FDA renews panel to advise on heart and kidney pills

## Summary

The Food and Drug Administration (FDA) is announcing the renewal of the Cardiovascular and Renal Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cardiovascular and Renal Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2028, expiration date.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-16999 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/20/2026-16999/advisory-committee-cardiovascular-and-renal-drugs-advisory-committee-renewal)
- [2026-16999 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-20/pdf/2026-16999.pdf)

## Related
- [Previous: 2026-16998, Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Rene…](https://policyrisk.com/federal-register/2026-16998)
- [Next: 2026-17000, Notice of Request for Clearance of a New Information Collection: Intermodal Fre…](https://policyrisk.com/federal-register/2026-17000)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16999 (as of 2026-08-27).
